In November 2023, Oncodia secured another round of financing of SEK 6.56M from existing shareholders to further proceed with an updated business strategy combining the company's software solutions for secondary…
Oncodia has the pleasure to announce the release of the best VARify to date; the CE marked IVD medical device software for tumor-normal mutation analysis. This release bridges the sequencing-by-synthesis…
Dear Customers, We are a proud exhibitor at the Nordic Precision Medicine Forum, which is taking place on the 28th-29th of April in Stockholm, Sweden. This event will explore the…
On 31st of March, Oncodia released the second major version of ALTOmate; the CE marked IVD medical device software for single-sample mutation analysis. This clinical-grade product was enhanced to serve…
On 30th of December, 2021 Oncodia released a scheduled update of ALTOmate to version 1.2.1. The new version improves the selectivity of the mutation output in regions with poor alignment…
On 29th of October, Oncodia released a scheduled update of VARify to version 1.1.0. The new version adequately solves the problem of conflicting requirements of the clinical centers. Some laboratories…
On 30th of September, 2021 Oncodia released a scheduled update of ALTOmate to version 1.2.0. The new version includes two modes of operation aimed to enhance the performance towards either…
The efforts of establishing the pioneering software solutions ALTOmate and VARify in clinics in Europe and North America, have led to a successful third investment round for the Uppsala-based company…
On 31th of May, 2021 Oncodia released a scheduled minor update of ALTOmate to version 1.1.0. The new version includes improved sensitivity, enhanced InDel alignment model and adjustments of the…
VARify is the new CE/IVD-certified software for precision analysis of tumor and patient-matched normal samples. VARify offers unprecedented selectivity by reporting higher number of clinically relevant mutation calls and less…